RVMD Biotechnology · Clinical-stage · Oncology · RAS inhibitors · Thesis updated June 12, 2026

A RAS winner, with big trial costs

Daraxonrasib hit a major Phase 3 win in second-line pancreatic cancer, with median overall survival of 13.2 months versus 6.7 months for chemotherapy.
The company had $1.9 billion in cash at March 31, 2026, then raised about $2.1 billion more in April 2026.
The pipeline now includes four clinical-stage RAS(ON) inhibitors, plus a next-generation class expected to enter human testing in Q4 2026.
The main bear case is cost: operating cash burn was $354 million in Q1 2026 as multiple late-stage trials scaled up.
New risks include an intellectual property dispute with Erasca and possible supply chain pressure from the BIOSECURE Act.

01 Running thesis

One trial changed the story

Revolution Medicines is no longer only a platform story. In April 2026, its lead drug daraxonrasib reported positive Phase 3 results in second-line pancreatic ductal adenocarcinoma, a hard-to-treat cancer often shortened to PDAC. The trial showed median overall survival of 13.2 months for daraxonrasib versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 and p value below 0.0001. In plain English, patients on the drug lived much longer in this study, and the result was very unlikely to be random.

That result does two things. First, it gives the company a clear path to file for approval in second-line PDAC. Second, it supports the idea behind its RAS(ON) platform, which tries to block the active form of RAS, a cancer-driving protein that was long seen as very hard to drug.

The balance sheet also changed fast. Revolution had $1.9 billion in cash, cash equivalents, and marketable securities at March 31, 2026. After the data, it completed stock and convertible note offerings with about $2.1 billion in net proceeds. That gives it room to fund late-stage trials and prepare for a possible launch.

The caution is that one win does not prove every use case. The stock still depends on more Phase 3 outcomes in lung cancer, first-line PDAC, adjuvant PDAC, and combinations. The company is spending at a very high pace, and new issues, including the Erasca IP dispute and China-linked supply chain risk under the BIOSECURE Act, could weigh on the story.

May 2026▲Daraxonrasib produced positive Phase 3 survival data in second-line PDAC, a major de-risking event for the lead drug. Revolution then raised about $2.1 billion, while also disclosing an Erasca IP dispute and a terminated Amgen collaboration.

Feb 2026▲The 2025 10-K confirmed steady clinical execution, including zoldonrasib Breakthrough Therapy Designation and an active first-in-human trial for RMC-5127. It also added BIOSECURE Act risk and showed R&D expense rising 67% to $987.3 million.

Nov 2025▲Daraxonrasib gained Orphan Drug Designation in pancreatic cancer and a Commissioner's National Priority Voucher. Revolution also initiated the Phase 3 RASolute 304 adjuvant PDAC study.

Aug 2025▲Royalty Pharma financing added up to $1.25 billion of non-dilutive capital. Daraxonrasib and elironrasib also gained FDA Breakthrough Therapy Designation, helping offset concerns about rising trial costs.

May 2025▲Early combination data in NSCLC and other settings supported the broader RAS(ON) platform. Cash remained high at $2.1 billion, but R&D expense rose 74% year over year in Q1 2025.

Feb 2025▲Revolution activated the Phase 3 RASolve 301 NSCLC study and mapped more Phase 3 starts for daraxonrasib. A December 2024 financing brought in $823.0 million of net proceeds.

Nov 2024▲Updated pancreatic cancer data for RMC-6236 showed median overall survival of 14.5 months in a prior study, supporting the Phase 3 plan. Early RMC-9805 data also showed a 30% overall response rate in the reported group.

Aug 2024→The starting thesis framed Revolution as a well-funded clinical-stage oncology company with a novel RAS(ON) platform. The main risks were unproven late-stage efficacy, high cash burn, and competition.

02 Business model

No drug sales yet

Revolution Medicines is a clinical-stage biotech. That means it does not yet sell an approved medicine. Its value comes from the chance that its drug candidates win approval, reach patients, and become commercial products.

The company builds small-molecule cancer drugs using structure-based design, chemical biology, and cancer pharmacology. Its main focus is RAS(ON) inhibitors. These drugs aim at the active, GTP-bound form of RAS, instead of the inactive RAS(OFF) form targeted by some older approaches.

Past revenue came from collaboration agreements, including the Sanofi SHP2 program that included an upfront payment and research reimbursements before that agreement ended in June 2023. Today, partnerships mainly help test combinations, such as the Bristol Myers Squibb study of daraxonrasib with navlimetostat and the Synnovation plan to test a PARP inhibitor with daraxonrasib in PDAC.

The model breaks if the drugs fail late trials, regulators reject the filings, manufacturing cannot scale, or launch uptake is weak. Even with a large cash balance, the company must turn science into approvals, reimbursement, and doctor use.

03 Product portfolio

A pipeline built around active RAS

Growth engine

Daraxonrasib, RMC-6236

This oral multi-selective RAS(ON) inhibitor is the lead program. Its Phase 3 RASolute 302 win in second-line PDAC supports a planned global regulatory submission.

Option

Elironrasib, RMC-6291

This oral G12C-selective RAS(ON) inhibitor has FDA Breakthrough Therapy Designation for KRAS G12C-mutated NSCLC after prior chemotherapy and immunotherapy. It is being tested alone and in combinations.

Option

Zoldonrasib, RMC-9805

This oral G12D-selective RAS(ON) inhibitor has FDA Breakthrough Therapy Designation for previously treated KRAS G12D-mutated NSCLC. Early human data showed acceptable tolerability and encouraging initial activity.

Option

RMC-5127

This G12V-selective RAS(ON) inhibitor is in a first-in-human dose escalation trial. It gives the company a fourth clinical-stage RAS(ON) program.

Option

Next-generation RAS(ON) inhibitors

These preclinical drugs are designed to overcome RAS-driven drug resistance. Revolution expects to start a first-in-human trial from this class in Q4 2026.

Option

RAS companion inhibitors

This group includes SHP2, mTORC1, and SOS1 inhibitors. Further development is subject to portfolio prioritization, so these are not the main value driver today.

04 Business segments

Spending shows the real focus

Daraxonrasib, RMC-6236 R&D52%growing fast

Zoldonrasib, RMC-9805 R&D19%growing fast

Elironrasib, RMC-6291 R&D12%growing fast

RMC-5127 R&D2%growing fast

RAS companion inhibitor R&D0%declining

Preclinical program R&D15%modest

Revolution reports as one research and development business, not as separate commercial segments. The mix below uses 2025 third-party R&D program spending, with shares calculated across the listed program categories.

05 Risk factors

What could still go wrong

Regulatory filing slips or rejection

High impact · Medium odds

The RASolute 302 data look strong, but approval is not automatic. The FDA and other regulators still need to review the full data package, safety profile, manufacturing package, and proposed label. Any delay would push out the first possible product revenue.

We watchNDA submission timing for daraxonrasib in second-line PDAC and any FDA acceptance, priority review, or PDUFA update.

Next Phase 3 trials disappoint

High impact · Medium odds

The bull case assumes daraxonrasib and other RAS(ON) drugs work beyond second-line PDAC. Trials in NSCLC, first-line PDAC, adjuvant PDAC, and combinations are costly and not guaranteed to match the lead result. A miss would shrink the market opportunity and challenge platform confidence.

We watchEnrollment and readouts from RASolve 301, RASolute 303, RASolute 304, and the planned RASolute 309 combination trial.

Cash burn stays very high

Medium impact · High odds

The company has a large cash balance, but spending is also large. Operating cash burn was $354 million in Q1 2026, and total R&D expense rose 67% in 2025 to $987.3 million. Launch preparation could add more cost before meaningful revenue begins.

We watchQuarterly operating cash burn, R&D expense growth, and any new financing or cost-control comments.

Erasca IP dispute expands

Medium impact · Medium odds

In April 2026, Revolution disclosed intellectual property matters involving Erasca. A dispute could become expensive and distract management. It could also lead to counterclaims that challenge Revolution's own patent position.

We watchAny lawsuit filings, settlement terms, injunction requests, or new patent office actions involving Erasca.

BIOSECURE Act supply chain pressure

Medium impact · Medium odds

The BIOSECURE Act could limit work with certain China-linked biotechnology companies. Revolution uses third-party manufacturing and has relationships with entities in China. As the company moves closer to launch, changing suppliers could cost time and money.

We watchCompany disclosures on China-exposed suppliers, manufacturing transfer plans, and BIOSECURE Act implementation rules.

06 Quick answers

In one breath

What does Revolution Medicines do?

Revolution Medicines develops targeted cancer drugs for tumors driven by RAS mutations. Its main approach is to block RAS in its active state, called RAS(ON).

Does Revolution Medicines have an approved drug?

No. It is still a clinical-stage company, but daraxonrasib now has positive Phase 3 data in second-line PDAC and is expected to be submitted to regulators.

Why was the RASolute 302 trial important?

It showed a clear survival benefit for daraxonrasib versus chemotherapy in second-line PDAC. The reported median overall survival was 13.2 months versus 6.7 months.

What is the biggest risk for RVMD stock?

The biggest risk is that more late-stage trials fail or regulators do not approve daraxonrasib. High cash burn, IP litigation, and supply chain rules are also important risks.